The Prime Minister and Health Secretary of the United Kingdom, Sir Keir Starmer, have expressed their optimism in the potential of new weight loss drugs. Wegovy and Mounjaro are treatments that function similarly to a hormone that suppresses hunger and as a result, can reduce obesity. Starmer claims it’s time to re-think the underlying issues of obesity and its detriment to both the economy and the National Health Service. Health Innovation Manchester, a group affiliated with the NHS and Eli Lilly, will lead trials investigating the benefits of Mounjaro for getting obese individuals back to work.
Obesity is a significant burden on both the economy and the health service. UK research estimates that obesity-related illnesses cost the NHS about £11bn a year, roughly 8% of its spending. The costs are compounded to almost £100bn annually, or 4% of gross domestic product, considering lost productivity in the economy. With continuous increases in obesity rates, weighing the benefits of new drugs alongside the cost to people and society as a whole remains vital.
A solution to the obesity crisis has evaded successive UK governments since the early 1990s. Past attempts to address obesity through promoting healthy lifestyle choices, labelling food, restricting unhealthy food advertisements, and introducing the sugar tax have been insufficient. Public spending on health has also been tightly limited for nearly a decade, stuck in budgetary constraints, which have limited the success of public health initiatives to address obesity and improve public well-being.
Despite the advantages that weight-loss drugs represent, health experts warn that they should not be viewed as a universal answer to obesity. The NHS highly restricts their use; semaglutide-based drugs are approved exclusively for treatment of diabetes, not obesity. The weight loss drug, Wegovy, is only available to a small population of severely obese individuals, along with stringent specialist oversight. Alternative rations, such as the Mounjaro drug, are not available as weight-loss treatments via the NHS but have been proposed in official drug-advisory findings. Pathways to increase access for the general public will require a structured program of exercise and diet adherence alongside the medication.
Finally, access expansion may be challenged by drug supply constraints since the private market has driven an increased demand for the medication, marketed as a “skinny jab.” There is concern that the drugs could promote a dependent culture, where a healthy lifestyle, physical exercise and diet are not often given priority. Thus, a broader effort is needed to combat the complex, multi-faceted factors that contribute to the UK’s obesity epidemic
Read the full article from The BBC here: Read More
